NewslettersHematopoiesis News Bio-Path Holdings Announces First Patient Dosed in Phase I/Ib Study of BP1002 in Refractory/Relapsed Acute Myeloid Leukemia Patients By Jamie Kang - October 24, 2022 0 Bio-Path Holdings, Inc. announced the enrollment and dosing of the first patient in a Phase I/Ib clinical trial evaluating the ability of BP1002 to treat refractory/relapsed acute myeloid leukemia patients. [Bio-Path Holdings, Inc.] Press Release